Real-world data are a well-recognized component within the drug lifecycle, and such data
are generated from a range of sources and study designs, including claims databases …

Background and Purpose—The use of oral anticoagulant therapy for stroke prevention in
atrial fibrillation has been transformed by the availability of the nonvitamin K antagonist oral …

Objective To compare the efficacy, safety, and cost effectiveness of direct acting oral
anticoagulants (DOACs) for patients with atrial fibrillation. Design Systematic review …

Abstract Introduction and Objectives Novel oral anticoagulants are emerging options for the
prevention and treatment of thromboembolic diseases. They are increasingly used in clinical …

Background The non-vitamin K antagonist oral anticoagulants (NOACs) overcame some
limitations of vitamin K antagonists (VKAs), and are at least as effective in stroke prevention …

Four recently introduced new oral anticoagulants (dabigatran, rivaroxaban, apixaban and
edoxaban) have been shown to be at least as efficacious and safe as warfarin for stroke …

Background and aim Current observational studies have compared the effectiveness and
safety of edoxaban with other oral anticoagulants in patients with AF, but the results are still …

Background: The novel direct oral anticoagulants (NOA), dabigatran (a thrombin inhibitor),
rivaroxaban and apixaban (factor Xa inhibitors) have shown at least noninferiority compared …

What is known and objective Anticoagulation is important in the management of
cardiovascular disorders; however, traditional anticoagulants such as heparins and vitamin …

Background: The aim of the study was to evaluate the efficacy and safety of direct oral
anticoagulants (DOACs) in a subgroup of patients with atrial fibrillation (AF), CHADS2 …